je.st
news
Tag: trial
Report: 11M Sign Up for Apple Music Trial
2015-08-24 01:02:21| PC Magazine MP3 Player Product Guide
Just how many of them will convert over to a paid subscription, though?
Defendant Pleads Guilty in Webb County Water Trial
2015-08-22 23:31:45| Waste Management - Topix.net
On the fourth day of a criminal trial involving undrinkable water in two border communities, one of the two defendants pleaded guilty to all charges against him. Luis Camacho, who oversaw operations at the Rio Bravo Water Treatment Plant until June 2014, admitted to four felony counts - three for tampering with government data and one for engaging in organized criminal activity.
Tags: water
county
trial
guilty
iPhone user? Samsungs offering you a free 30-day trial of a Galaxy S6 Edge or Note 5
2015-08-21 18:37:02| Extremetech
If you're an iPhone user who is curious about the other side, Samsung has a deal for you. Pay $1 and get a cutting-edge device of your choice -- complete with a functional SIM card for your network provider.
New Analyses from the IMPROVE-IT Outcomes Study of VYTORIN (ezetimibe and simvastatin) and the TECOS Cardiovascular Safety Trial of JANUVIA (sitagliptin) Will Be Presented at the European Society of Cardiology Congress
2015-08-20 14:30:00| Merck.com - Product News
Dateline City: KENILWORTH, N.J. Additional Real-World Analyses from DYSIS and DYSIS II Assessing the Treatment of Dyslipidemia to be Presented KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, announced today that new analyses from the investigational IMPROVE-IT (IMProved Reduction of Outcomes: VYTORIN Efficacy International Trial) study of VYTORIN (ezetimibe and simvastatin), the TECOS (Trial Evaluating Cardiovascular Outcomes with Sitagliptin) cardiovascular safety trial of JANUVIA (sitagliptin), and real-world data from the Dyslipidemia International Study (DYSIS I and DYSIS II) will be presented at the upcoming European Socie Language: English Contact: MerckMedia:Pamela Eisele, 267-305-3558orKim Hamilton, 908-391-0131orInvestor:Justin Holko, 908-740-1879 Ticker Slug: Ticker: MRK Exchange: NYSE read more
First Self-Injectable HIV Antibody: 98% Success Rate In Phase 2b Clinical Trial, Could Be Commercial In 2017
2015-08-19 07:01:19| drugdiscoveryonline Home Page
The first self-injectable antibody, PRO 140, has documented an impressive 98% success rate in a Phase 2b clinical trial for patients with HIV. In a monotherapy study, some HIV patients using PRO 140 are experiencing a completely suppressed viral load for 11 months.
Tags: in
rate
commercial
trial
Sites : [76] [77] [78] [79] [80] [81] [82] [83] [84] [85] [86] [87] [88] [89] [90] [91] [92] [93] [94] [95] next »